Primobolan 100

primobolan 100 dragon pharmaPrimobolan 100 by Dragon Pharma is indicated for treatment of aplastic anaemia which are or may be responsive to anabolic androgens, cachexia and replacement therapy for males with androgenic deficiencies.

Primobolan 100 is a Dihydro-Testosterone (DHT) based anabolic steroid. It is an ester derivative of Methenolone sold commonly under the brand names Primobolan (tablet form) or Primobolan Depot (injectable). When it interacts with the aromatase enzyme it does not form any estrogens. It is used by people who are very susceptible to estrogenic side effects, having lower estrogenic properties than Nandrolone.

Methenolone Enanthate and Acetate, are available in both tablet and injectable form. is available as an injection or as an oral respectively. The injection is naturally regarded as having a higher bio-availability. It is an Enanthate ester which is quite long-acting and because it by-passes hepatic breakdown on the first pass, it also has a higher survival rate.

The tablets are in a short-lived acetate form. Methenolone is not 17-alpha-alkylated, but 1-methylated for oral bio-availability. This reduces the stress on the liver, but also the availability. It is considered one of the safer steroids, meaning it has few side effects.

Primobolan 100 has no estrogenic side effects, and its effects on cholesterol levels are minimal. In doses of 200 mg per week or less (intramuscular) blood pressure is rarely altered. It is possibly one of the safer anabolic steroids for females due to very low virilization effects in short-term usage. Dragon Pharma Primobolan 100 is also not overly suppressive of the hypothalamic-pituitary-gonadal axis, although how much so is debatable. For this reason, many bodybuilders use Primobolan 100 in between steroid cycles during their “off-time” to help maintain their gains and strength. The long term safety of such a practice is possibly dangerous and can lead to permanent suppression of the HPTA.

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll Up